138
Participants
Start Date
February 8, 2021
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2026
Verapamil SR 120 mg
"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
Placebo
"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism, Graz
Universitair Ziekenhuis Brussel, Brussels
Université Libre de Bruxelles/ Hôpital Erasme, Brussels
Universitair Ziekenhuis Antwerpen, Edegem
Katholieke Universiteit Leuven, Leuven
Institut National de la Santé et de la Recherche Médicale, Paris
HKA Hannover, Hanover
Universität Ulm, Ulm
Università Vita-Salute San Raffaele, Milan
Università degli Studi di Siena, Siena
Queen Elizabeth Hospital, Birmingham
Southmead Hospital, Bristol
Addenbrokes Hospital, Cambridge
University Hospital of Wales, Cardiff
NHS Greater Glasgow and Clyde-Queen Elizabeth University Hospital, Department of Diabetes, Glasgow
Bart's Hospital QMUL, London
Guy's Hospital, London
Queens Medical Centre, Nottingham
John Radcliffe Hospital, Oxford
OCDEM, John Radcliffe Hospital, Oxford
Royal Hallamshire Hospital, Sheffield
Singleton Hospital, Swansea
Collaborators (1)
Juvenile Diabetes Research Foundation
OTHER
Medical University of Graz
OTHER